RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

Cell Reports

Volumn 8, Issue 5, 2014, Pages 1475-1483

  Lamba, Simona ^a,b   Russo, Mariangela ^a,b   Sun, Chong ^c   Lazzari, Luca ^a,b,d   Cancelliere, Carlotta ^b   Grernrum, Wipawadee ^c   Lieftink, Cor ^c   Bernards, Rene ^c   DiNicolantonio, Federica ^a,b   Bardelli, Alberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; RAF PROTEIN; SELUMETINIB; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

ALLOSTERISM; APOPTOSIS; ARTICLE; CANCER CELL; CELL MUTANT; CELL VIABILITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; ENZYME INHIBITION; ENZYME REPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG CANCER CELL LINE; ONCOGENE K RAS; PHENOTYPE; PROTEIN CLEAVAGE; REVERSE GENETICS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; COLORECTAL TUMOR; GENETICS; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS; RAF KINASES; RAS PROTEINS;

EID: 84922485593     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.07.033     Document Type: Article

References (30)

1. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., Hanson L.J., Gore L., Chow L., Leong S., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J.Clin. Oncol. 2008, 26:2139-2146.
2. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., et al. Functional viability profiles of breast cancer. Cancer Discov. 2011, 1:260-273.
3. Carlino M.S., Todd J.R., Gowrishankar K., Mijatov B., Pupo G.M., Fung C., Snoyman S., Hersey P., Long G.V., Kefford R.F., Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 2014, 8:544-554.
4. Cox A.D., Der C.J. Ras history: The saga continues. Small GTPases 2010, 1:2-27.
5. Douillard J.Y., Oliner K.S., Siena S., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N.Engl. J. Med. 2013, 369:1023-1034.
6. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J.Clin. Invest. 2011, 121:4311-4321.
7. Faber A.C., Coffee E.M., Costa C., Dastur A., Ebi H., Hata A.N., Yeo A.T., Edelman E.J., Song Y., Tam A.T., et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014, 4:42-52.
8. Ganesan P., Janku F., Naing A., Hong D.S., Tsimberidou A.M., Falchook G.S., Wheler J.J., Piha-Paul S.A., Fu S., Stepanek V.M., et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol. Cancer Ther. 2013, 12:2857-2863.
9. Garnett M.J., Rana S., Paterson H., Barford D., Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 2005, 20:963-969.
10. Gysin S., Salt M., Young A., McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
11. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N.Engl. J. Med. 2008, 359:1757-1765.
12. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., Papadimitriou C.A., Murray S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9:962-972.
13. Lito P., Saborowski A., Yue J., Solomon M., Joseph E., Gadal S., Saborowski M., Kastenhuber E., Fellmann C., Ohara K., et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 2014, 25:697-710.
14. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 2003, 3:459-465.
15. Misale S., Arena S., Lamba S., Siravegna G., Lallo A., Hobor S., Russo M., Buscarino M., Lazzari L., Sartore-Bianchi A., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 2014, 6:224ra226.
16. Molina-Arcas M., Hancock D.C., Sheridan C., Kumar M.S., Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013, 3:548-563.
17. Montagut C., Sharma S.V., Shioda T., McDermott U., Ulman M., Ulkus L.E., Dias-Santagata D., Stubbs H., Lee D.Y., Singh A., et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008, 68:4853-4861.
18. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
19. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
20. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72:2457-2467.
21. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
22. Roth A.D., Delorenzi M., Tejpar S., Yan P., Klingbiel D., Fiocca R., d'Ario G., Cisar L., Labianca R., Cunningham D., et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J.Natl. Cancer Inst. 2012, 104:1635-1646.
23. Smith C.G., Fisher D., Claes B., Maughan T.S., Idziaszczyk S., Peuteman G., Harris R., James M.D., Meade A., Jasani B., et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res. 2013, 19:4104-4113.
24. Su Y., Vilgelm A.E., Kelley M.C., Hawkins O.E., Liu Y., Boyd K.L., Kantrow S., Splittgerber R.C., Short S.P., Sobolik T., et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin. Cancer Res. 2012, 18:2184-2198.
25. Sun C., Hobor S., Bertotti A., Zecchin D., Huang S., Galimi F., Cottino F., Prahallad A., Grernrum W., Tzani A., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Reports 2014, 7:86-93.
26. Turke A.B., Song Y., Costa C., Cook R., Arteaga C.L., Asara J.M., Engelman J.A. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012, 72:3228-3237.
27. Van Schaeybroeck S., Kalimutho M., Dunne P.D., Carson R., Allen W., Jithesh P.V., Redmond K.L., Sasazuki T., Shirasawa S., Blayney J., et al. ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports 2014, 7:1940-1955.
28. Whittaker S.R., Theurillat J.P., Van Allen E., Wagle N., Hsiao J., Cowley G.S., Schadendorf D., Root D.E., Garraway L.A. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013, 3:350-362.
29. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12:553-563.
30. Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.